Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis

BACKGROUND: Brolucizumab is a new anti-vascular endothelial growth factor (anti-VEGF) approved for treating neovascular age-related macular degeneration (nAMD). Multiple treatment regimens are available for treating nAMD. These regimens include manufacturer-recommended regimens, pro re nata (PRN) re...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqui, Zasim Azhar, Dhumal, Trupti, Patel, Jay, LeMasters, Traci, Almony, Arghavan, Kamal, Khalid M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373014/
https://www.ncbi.nlm.nih.gov/pubmed/36427338
http://dx.doi.org/10.18553/jmcp.2022.28.12.1350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373014/
https://www.ncbi.nlm.nih.gov/pubmed/36427338
http://dx.doi.org/10.18553/jmcp.2022.28.12.1350

Ejemplares similares